Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells

Robert J. Coffey, Chris J. Hawkey, Lars Damstrup, Ramona Graves-Deal, Vincent C. Daniel, Peter J. Dempsey, Rebecca Chinery, Susan C. Kirkland, Raymond N. Dubois, Thomas L. Jetton, Jason D. Morrow

Research output: Contribution to journalArticle

287 Citations (Scopus)

Abstract

Nonsteroidal antiinflammatory drugs reduce the risk of colon cancer, possibly via cyclooxygenase (COX) inhibition. The growth factor-inducible COX-2, which is overexpressed in neoplastic colonic tissue, is an attractive target to mediate this effect. Herein we have exploited the ability of a human colon cancer cell line, HCA-7 Colony 29, to polarize when cultured on Transwell (Costar) filters to study COX-2 production and the vectorial release of prostaglandins (PGs). Administration of type α transforming growth factor to the basolateral compartment, in which the epidermal growth factor receptor (EGFR) resides, results in a marked induction of COX-2 immunoreactivity at the base of the cells and the unexpected appearance of COX-2 in the nucleus. The increase in COX-2 protein is associated with a dose- and time-dependent increase in PG levels in the basolateral, but not apical, medium. Amphiregulin is the most abundantly expressed EGFR ligand in these cells, and the protein is present at the basolateral surface. EGFR blockade reduces baseline COX-2 immunoreactivity, PG levels, and mitogenesis in a concentration-dependent manner. Two specific COX-2 inhibitors, SC-58125 and NS 398, also, in a dose-dependent manner, attenuate baseline and type α transforming growth factor-stimulated mitogenesis, although PG levels are decreased >90% at all concentrations of inhibitor tested. These findings show that activation of the EGFR stimulates COX-2 production and its translocation to the nucleus, vectorial release of PGs, and mitogenesis in polarized HCA-7 Colony 29 cells.

Original languageEnglish (US)
Pages (from-to)657-662
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume94
Issue number2
DOIs
StatePublished - Jan 21 1997
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Epidermal Growth Factor Receptor
Colonic Neoplasms
Prostaglandins
Transforming Growth Factors
Cyclooxygenase 2 Inhibitors
Prostaglandin-Endoperoxide Synthases
Intercellular Signaling Peptides and Proteins
Proteins
Anti-Inflammatory Agents
Ligands
Cell Line
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. / Coffey, Robert J.; Hawkey, Chris J.; Damstrup, Lars; Graves-Deal, Ramona; Daniel, Vincent C.; Dempsey, Peter J.; Chinery, Rebecca; Kirkland, Susan C.; Dubois, Raymond N.; Jetton, Thomas L.; Morrow, Jason D.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, No. 2, 21.01.1997, p. 657-662.

Research output: Contribution to journalArticle

Coffey, Robert J. ; Hawkey, Chris J. ; Damstrup, Lars ; Graves-Deal, Ramona ; Daniel, Vincent C. ; Dempsey, Peter J. ; Chinery, Rebecca ; Kirkland, Susan C. ; Dubois, Raymond N. ; Jetton, Thomas L. ; Morrow, Jason D. / Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. In: Proceedings of the National Academy of Sciences of the United States of America. 1997 ; Vol. 94, No. 2. pp. 657-662.
@article{60a89fb07a7c45bbb57e7d033ea089e8,
title = "Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells",
abstract = "Nonsteroidal antiinflammatory drugs reduce the risk of colon cancer, possibly via cyclooxygenase (COX) inhibition. The growth factor-inducible COX-2, which is overexpressed in neoplastic colonic tissue, is an attractive target to mediate this effect. Herein we have exploited the ability of a human colon cancer cell line, HCA-7 Colony 29, to polarize when cultured on Transwell (Costar) filters to study COX-2 production and the vectorial release of prostaglandins (PGs). Administration of type α transforming growth factor to the basolateral compartment, in which the epidermal growth factor receptor (EGFR) resides, results in a marked induction of COX-2 immunoreactivity at the base of the cells and the unexpected appearance of COX-2 in the nucleus. The increase in COX-2 protein is associated with a dose- and time-dependent increase in PG levels in the basolateral, but not apical, medium. Amphiregulin is the most abundantly expressed EGFR ligand in these cells, and the protein is present at the basolateral surface. EGFR blockade reduces baseline COX-2 immunoreactivity, PG levels, and mitogenesis in a concentration-dependent manner. Two specific COX-2 inhibitors, SC-58125 and NS 398, also, in a dose-dependent manner, attenuate baseline and type α transforming growth factor-stimulated mitogenesis, although PG levels are decreased >90{\%} at all concentrations of inhibitor tested. These findings show that activation of the EGFR stimulates COX-2 production and its translocation to the nucleus, vectorial release of PGs, and mitogenesis in polarized HCA-7 Colony 29 cells.",
author = "Coffey, {Robert J.} and Hawkey, {Chris J.} and Lars Damstrup and Ramona Graves-Deal and Daniel, {Vincent C.} and Dempsey, {Peter J.} and Rebecca Chinery and Kirkland, {Susan C.} and Dubois, {Raymond N.} and Jetton, {Thomas L.} and Morrow, {Jason D.}",
year = "1997",
month = "1",
day = "21",
doi = "10.1073/pnas.94.2.657",
language = "English (US)",
volume = "94",
pages = "657--662",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "2",

}

TY - JOUR

T1 - Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells

AU - Coffey, Robert J.

AU - Hawkey, Chris J.

AU - Damstrup, Lars

AU - Graves-Deal, Ramona

AU - Daniel, Vincent C.

AU - Dempsey, Peter J.

AU - Chinery, Rebecca

AU - Kirkland, Susan C.

AU - Dubois, Raymond N.

AU - Jetton, Thomas L.

AU - Morrow, Jason D.

PY - 1997/1/21

Y1 - 1997/1/21

N2 - Nonsteroidal antiinflammatory drugs reduce the risk of colon cancer, possibly via cyclooxygenase (COX) inhibition. The growth factor-inducible COX-2, which is overexpressed in neoplastic colonic tissue, is an attractive target to mediate this effect. Herein we have exploited the ability of a human colon cancer cell line, HCA-7 Colony 29, to polarize when cultured on Transwell (Costar) filters to study COX-2 production and the vectorial release of prostaglandins (PGs). Administration of type α transforming growth factor to the basolateral compartment, in which the epidermal growth factor receptor (EGFR) resides, results in a marked induction of COX-2 immunoreactivity at the base of the cells and the unexpected appearance of COX-2 in the nucleus. The increase in COX-2 protein is associated with a dose- and time-dependent increase in PG levels in the basolateral, but not apical, medium. Amphiregulin is the most abundantly expressed EGFR ligand in these cells, and the protein is present at the basolateral surface. EGFR blockade reduces baseline COX-2 immunoreactivity, PG levels, and mitogenesis in a concentration-dependent manner. Two specific COX-2 inhibitors, SC-58125 and NS 398, also, in a dose-dependent manner, attenuate baseline and type α transforming growth factor-stimulated mitogenesis, although PG levels are decreased >90% at all concentrations of inhibitor tested. These findings show that activation of the EGFR stimulates COX-2 production and its translocation to the nucleus, vectorial release of PGs, and mitogenesis in polarized HCA-7 Colony 29 cells.

AB - Nonsteroidal antiinflammatory drugs reduce the risk of colon cancer, possibly via cyclooxygenase (COX) inhibition. The growth factor-inducible COX-2, which is overexpressed in neoplastic colonic tissue, is an attractive target to mediate this effect. Herein we have exploited the ability of a human colon cancer cell line, HCA-7 Colony 29, to polarize when cultured on Transwell (Costar) filters to study COX-2 production and the vectorial release of prostaglandins (PGs). Administration of type α transforming growth factor to the basolateral compartment, in which the epidermal growth factor receptor (EGFR) resides, results in a marked induction of COX-2 immunoreactivity at the base of the cells and the unexpected appearance of COX-2 in the nucleus. The increase in COX-2 protein is associated with a dose- and time-dependent increase in PG levels in the basolateral, but not apical, medium. Amphiregulin is the most abundantly expressed EGFR ligand in these cells, and the protein is present at the basolateral surface. EGFR blockade reduces baseline COX-2 immunoreactivity, PG levels, and mitogenesis in a concentration-dependent manner. Two specific COX-2 inhibitors, SC-58125 and NS 398, also, in a dose-dependent manner, attenuate baseline and type α transforming growth factor-stimulated mitogenesis, although PG levels are decreased >90% at all concentrations of inhibitor tested. These findings show that activation of the EGFR stimulates COX-2 production and its translocation to the nucleus, vectorial release of PGs, and mitogenesis in polarized HCA-7 Colony 29 cells.

UR - http://www.scopus.com/inward/record.url?scp=12644261426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12644261426&partnerID=8YFLogxK

U2 - 10.1073/pnas.94.2.657

DO - 10.1073/pnas.94.2.657

M3 - Article

VL - 94

SP - 657

EP - 662

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 2

ER -